News

Discover how veteran finance executive Tim Gillespie, CFA, joins Biosenta as a strategic advisor to enhance their antimicrobial technology strategy.

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

Validated University of Calgary research demonstrates broad-spectrum efficacy of core-shell calcium hydroxide-calcium carbonate (CSCC(TM)) particles. Biosenta Inc. announced that two independent, peer-reviewed studies confirmed that its proprietary Tri-Filler™ nanoparticles achieved complete (100%) bactericidal activity against multiple World Health Organization (WHO) priority pathogens and keep working far longer than conventional biocides.

A University of Calgary research team, partnered with Biosenta Inc., has developed a method to transform limestone into a long-lasting antimicrobial nanoparticle. This new "shell and core" technology has a durable active ingredient, calcium hydroxide, and has been proven effective against various harmful pathogens. Potential applications include enhancing concrete, paint for healthcare settings, and coatings for food packaging and high-touch surfaces.

Kris Hans shares how Biosenta is tackling the antimicrobial health crisis at the source, and why this work matters now more than ever.

Biosenta Inc. Achieves Major Breakthroughs in Bench Scale Production and Innovative Input Viability.

Biosenta announces significant advancements at its state-of-the-art bench scale production facility.

Biosenta has been making the innovative strides in the realm of antimicrobial biotechnology.

Biosenta Inc. announces licensing agreement

Biosenta granted to Lightweight Concrete Solutions a license to use Biosenta’s Tri-Filler® technology and get fee of C$200,000 and royalties

Biosenta announces technological and operational advancements with successful construction and operation of a bench scale production plant.

Discover Biosenta's exciting engagement with Oak Hill Financial, offering insight into their business and capital markets advisory services.

Discover how Biosenta successfully closed a private placement financing of $500,000 for its future growth and development.

Biosenta announces a pivotal discovery revealed that Tri-Filler™ effectively sterilizes a wide range of microorganisms.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta Inc. announces further advances in research and development of Tri-Filler™

Biosenta Inc. announces further advances in research and development of the Tri-Filler™ particle.

Chelsey Reschke is one of 47 Canadians attending the G20 Young Entrepreneurs’ Alliance summit in Hamburg from Oct. 27 to 28.

Biosenta Inc. has signed an MOU with Voran Group Ventures Ltd. for the commercialization of Biosenta’s Tri-Filler® antimicrobial products.